Chemomab Therapeutics (CMMB) Capital Expenditures Growth (1y) (2019 - 2023)
Chemomab Therapeutics (CMMB) Capital Expenditures Growth (1y) (2019 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 143.40% |
| 10 | Chemomab Therapeutics | 721.97 Mn | 711.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -95.56% |
| Jun 30, 2023 | 89.74% |
| Mar 31, 2023 | -92.86% |
| Dec 31, 2022 | 0.75% |
| Jun 30, 2022 | -138.24% |
| Mar 31, 2022 | 366.67% |
| Dec 31, 2021 | 13,300.00% |
| Jun 30, 2021 | 1,357.14% |
| Mar 31, 2021 | -70.00% |
| Dec 31, 2020 | -99.39% |
| Sep 30, 2020 | 112.42% |
| Jun 30, 2020 | 110.61% |
| Mar 31, 2020 | -93.63% |
| Dec 31, 2019 | -58.75% |
| Sep 30, 2019 | -80.90% |